Dermapharm has November 12 results. Dermapharm stock sits 26.30 percent below its high

Published on 10/20/2026 at 18:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 2.90 percent in first-half 2026. Dermapharm stock costs EUR 38.30 on October 20, 2026, up 0.13 percent versus Xetra close.

Results date and margins

Dermapharm has scheduled its next results for November 12, 2026.
Adjusted EBITDA rose 10.30 percent to EUR 163.20 million in the first half of 2026.
Dermapharm stock costs EUR 38.30 at Lang & Schwarz on October 20, 2026 at 6:39 p.m. CEST, 0.13 percent above the Xetra close of October 20, 2026.
The company trades at a P/E ratio of 13.81 with a market capitalization of EUR 1.9 billion.

Aquarell von Grünwald bei München mit bayerischen Häusern und Unternehmensgebäude — Dermapharm Holding DE000A2GS5D8 in Aquarelloptik: Firmensitz in Grünwald bei München inmitten bayerischer Landschaft mit Kirchturm, Illustration mit AI erstellt.

Dermapharm has an earnings date of November 12, 2026, while its stock sits 26.30 percent below its 52-week high of EUR 51.90. Yahoo Finance lists November 12, 2026 as the next earnings date. Dermapharm stock was trading at EUR 38.30 at Lang & Schwarz on October 20, 2026 at 6:39 p.m. CEST, up 0.13 percent versus the Xetra close of October 20, 2026 at EUR 38.25.

Revenue growth stayed moderate

Dermapharm reported revenue of EUR 591.00 million for the first half of 2026, up 2.90 percent from EUR 574.50 million in the first half of 2025. Adjusted EBITDA grew 10.30 percent to EUR 163.20 million from EUR 148.00 million, lifting the adjusted EBITDA margin to 27.60 percent from 25.80 percent. These figures were reported by FNE on October 14, 2026.

What does the price position say?

The October 20, 2026 52-week range runs from EUR 32.40 to EUR 51.90, placing the Lang & Schwarz price EUR 13.60 below the high and EUR 5.90 above the low. The stock's market value was EUR 1.9 billion on October 20, 2026, while trading volume reached 11,367 shares. The price position gives the scheduled results date a clear numerical frame, without establishing a causal link between the quotation and the reporting calendar.

Valuation and peer comparison

Dermapharm's P/E ratio was 13.81 on October 20, 2026, compared with 16.36 for Fresenius SE & Co. KGaA and 26.86 for Merck KGaA. The valuation comparison is descriptive rather than a forecast. Dermapharm's 2026 outlook calls for revenue of EUR 1,182.00 million to EUR 1,218.00 million and adjusted EBITDA of EUR 331.00 million to EUR 341.00 million, according to FNE.

Comparison with peers

Dermapharm: up 0.13 percent, P/E 13.81, market capitalization EUR 1.9 billion as of October 20, 2026.

Fresenius (Xetra, EUR): up 0.21 percent, P/E 16.36, market capitalization EUR 25.3 billion as of October 20, 2026.

Merck KGaA (Xetra, EUR): up 1.42 percent, P/E 26.86, market capitalization EUR 63.7 billion as of October 20, 2026.

Results date sets the next checkpoint

November 12, 2026 is the next dated checkpoint for Dermapharm. The first-half figures point to faster adjusted EBITDA growth than revenue growth, while the quotation remains materially below its yearly high.

The further course of trading is shown by the continuously updated real-time quote of Dermapharm stock.